Skip to main content
. Author manuscript; available in PMC: 2017 Jan 15.
Published in final edited form as: Clin Cancer Res. 2015 Oct 7;22(2):448–458. doi: 10.1158/1078-0432.CCR-15-0256

Figure 2.

Figure 2

ASPN expression in prostate cancer associated fibroblasts is associated with Gleason grade and oncologic outcomes. A, ASPN expression as determined by IHC in prostate tissue following radical prostatectomy. B, ASPN expression in prostate cancer associated fibroblasts in prostate tissue following radical prostatectomy as determined by IF of ASPN and pancytokeratin at 400× magnification. C, ASPN expression in human primary prostate cancer associated fibroblasts (PCAF), human primary benign prostate associated fibroblasts (BAF), an immortalized human benign prostate fibroblast cell line (WPMY1), primary human benign prostate epithelial cells (PreC), and human prostate cancer cell lines (LNCaP, 22RV1, PC3) as determined by qRT-PCR (top) and immunoblotting (bottom). D, ASPN expression as determined by IHC in JHU TMAs containing stroma adjacent to benign (n=48), Gleason sum ≤6 (n=31), Gleason sum 7 (n=6), and Gleason sum 8–9 (n=27) prostate tissue. Statistical analysis performed by one-way ANOVA with Tukey’s multiple comparison test (mean ± SEM; **P≤ 0.001, ***P ≤ 0.0001; upper). ASPN staining in human prostate cancer sections at 200× magnification (lower). E, ASPN expression is associated with biochemical recurrence (BCR). Kaplan–Meier survival curves of ASPN in MSKCC and in Mayo High Risk Cohort for BCR-free survival. F, ASPN expression is associated with metastatic recurrence. Kaplan–Meier survival curves of ASPN in Mayo High Risk Cohort for metastatic recurrence.